Naltrexone vs Acamprosate and Disulfiram
Naltrexone, acamprosate, and disulfiram have different goals, contraindications, and evidence. There is no universal best medicine.
Three medicines doing different jobs
- Naltrexone and acamprosate each have their own strengths, so your treatment goals and health history decide which fits.
- Standard acamprosate dosing is 666 mg three times daily in adults with normal renal function. That is 666 mg at each dose, and the daily total is higher.
- Acamprosate is contraindicated in severe renal impairment, and the liver does not do most of its processing.
- With naltrexone, your current opioid use and liver status need attention.
- Disulfiram can cause a potentially serious reaction with alcohol, so it needs careful education and careful selection of who takes it.
Medication comparison
| Naltrexone | Acamprosate | Disulfiram | |
|---|---|---|---|
| Common goal | Reduce heavy drinking or support abstinence | Maintain abstinence after withdrawal | Create a deterrent to drinking |
| Typical adult schedule | Often 50 mg daily; follow the product label and clinician plan | 666 mg three times daily with normal renal function; lower dose in moderate renal impairment | Individualized daily dosing under clinician supervision |
| Major organ consideration | Liver history and symptoms; current opioids are critical | Kidney function; contraindicated in severe renal impairment | Liver and cardiovascular risks among several contraindications |
| If alcohol is consumed | No disulfiram-like reaction; impairment and alcohol toxicity still occur | No direct deterrent reaction | Acetaldehyde reaction can be severe |
| Evidence position | Common first-line option | Common first-line option | Selected patients; adherence and supervision matter |
The choice is not just an efficacy ranking
A medicine can be effective in trials but unsuitable for a particular person. Clinicians also consider:
- current treatment goal;
- recent opioid use or expected opioid pain treatment;
- kidney and liver function;
- pregnancy and breastfeeding;
- adherence pattern and dosing burden;
- concurrent medicines and mental health;
- availability, registration, and cost in the local market.
Country availability needs product-level verification
Availability should not be inferred from an educational medicine page or from another country. Our current checks found strong standalone-naltrexone product evidence in Australia, New Zealand, South Africa, the UK, US, and Canada. In Singapore and the UAE, current public records more clearly establish the naltrexone/bupropion combination product than standalone 50 mg naltrexone.
Acamprosate and disulfiram vary the same way. Check the exact product in your own country, because “available” or “unavailable” alone would mislead you.
Sources
- DailyMed: acamprosate prescribing information. Dosing and renal contraindication.
- DailyMed: naltrexone tablet prescribing information. Opioid and hepatic warnings.
- NICE CG115 recommendations. Positions acamprosate and oral naltrexone after assisted withdrawal.